索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈佳佳,孙育民,魏雅丽.肥厚型心肌病合并心房颤动的抗凝治疗[J].国际心血管病杂志,2023,01:17-19.
点击复制

肥厚型心肌病合并心房颤动的抗凝治疗(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年01期
页码:
17-19
栏目:
综述
出版日期:
2023-01-20

文章信息/Info

Title:
-
作者:
陈佳佳; 孙育民; 魏雅丽
200040 上海，复旦大学附属静安区中心医院心内科
Author(s):
-
关键词:
非维生素K 拮抗剂口服抗凝药; 维生素K 拮抗剂口服抗凝药; 肥厚型心肌病;  心房颤动; 导管消融
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.01.005
文献标识码:
-
摘要:
肥厚型心肌病（HCM）是一种异质性遗传性心肌疾病，是心房颤动（房颤）患 者卒中和全身性血栓栓塞的独立危险因素。HCM 合并房颤的患者应尽早进行抗凝治疗，非 维生素K 拮抗剂口服抗凝药（NOAC）在HCM 合并房颤患者中应用的证据相对较少，但有 限的研究提示NOAC 具有一定优势，指南也推荐其为一线用药。
Abstract:
-

参考文献/References

[1] Keane S, Fabre A, Keane D. Characterization of atrial histology in a patient with hypertrophic cardiomyopathy: possible evidence of a primary atrial myopathy[J]. HeartRhythm Case Rep, 2021, 7(6):413-417.
[2] Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12):1249-1254.
[3] Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy[J]. Lancet, 2017, 389(10075):1253-1267.
[4] Alcalai RO, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics[J]. J Cardiovasc Electrophysiol, 2008, 19(1):104-110.
[5] 宋雷, 邹玉宝, 汪道文, 等. 中国成人肥厚型心肌病诊断与治 疗指南[J]. 中华心血管病杂志, 2017, 45(12):1015-1032.
[6] Creta A, Hunter RJ, Earley MJ, et al. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2020, 31(10):2626-2631.
[7] Nasser MF, Gandhi S, Siegel RJ, et al. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review[J]. Heart Rhythm, 2021, 18(2):297-302.
[8] Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J]. Heart, 2017, 103(19):1496-1501.
[9] Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population[J]. J Am Heart Assoc, 2014, 3(3):e001002.
[10] Tsuda T, Hayashi KS, Fujino N, et al. Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation[J]. Heart Rhythm, 2019, 16(6):829-837.
[11] Frontera A, Wilson DG, Sekhon H, et al. Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?[J]. Clin Res Cardiol, 2015, 104(10):799-802.
[12] Hindricks G, Potpara T, DagresN,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J, 2021, 42(5):373-498.
[13] Zhou YG, He WF, Zhou Y, et al. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis[J]. J Thromb Thrombolysis, 2020, 50(2):311- 317.
[14] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. Circulation, 2011, 124(24):e783-e831.
[15] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC)[J]. Eur Heart J, 2014, 35(39):2733-2779.
[16] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2020, 142(25):e533-e557.
[17] Noseworthy PA, Yao AA, Shah ND, et al. Stroke and bleeding risks in NOAC- and Warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Am Coll Cardiol, 2016, 67(25):3020-3021.
[18] Lee HJ, Kim HK, Jung JH, et al. Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation[J]. Stroke, 2019, 50(9):2582- 2586.
[19] Jung H, Yang PS, Jang E, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study[J]. Chest, 2019, 155(2):354-363.
[20] Dominguez F, Climent V, Zorio E, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. Int J Cardiol, 2017, 248:232-238.
[21] Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace, 2021, 23(10):1612-1676.
[22] Bhogal S, Mawa K, Bhandari T, et al. Use of NOACs versus vitamin K antagonist in atrial fibrillation catheter ablation: an updated meta-analysis with subgroup analysis[J]. Am J Ther, 2021, 29(1):e56-e63.
[23] Yang Q, Chen XF, Zhai JL, et al. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials[J]. Acta Cardiol, 2022, 77(3):257- 263.

备注/Memo

备注/Memo:
通信作者：魏雅丽，E-mail：1802549581@qq.com
更新日期/Last Update: 2023-01-20